MCID: CHR417
MIFTS: 55

Chronic Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

Summaries for Chronic Graft Versus Host Disease

GARD : 20 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and acute graft versus host disease. An important gene associated with Chronic Graft Versus Host Disease is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Fludarabine and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and t cells, and related phenotypes are poor wound healing and intermittent generalized erythematous papular rash

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 563)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.7 IL1A IL10 IFNG
2 acute graft versus host disease 31.8 IL2RA IL10 IFNG
3 bronchiolitis 31.5 IL10 IFNG CCL5
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.3 TNFSF13B IL10 IFNG
5 keratoconjunctivitis sicca 31.1 TNFSF13B IL1A CD79A
6 myasthenia gravis 31.0 TNFSF13B IL10 IFNG
7 chickenpox 30.8 IL10 IFNG
8 oral lichen planus 30.7 IL1A CCR5 CCL5
9 post-transplant lymphoproliferative disease 30.7 IL1A IL10
10 skin disease 30.7 IL1A IL10 IFNG CD79A
11 aplastic anemia 30.7 IL2RA IL1A IL10 IFNG
12 eye disease 30.7 IL1A IL10 IFNG CCL5
13 chronic inflammatory demyelinating polyradiculoneuropathy 30.6 IL10 IFNG CCL5
14 immunoglobulin alpha deficiency 30.6 TNFSF13B CD79A
15 pneumonia 30.5 IL10 IFNG CCL5
16 erythema multiforme 30.5 IFNG CCL5
17 polyradiculoneuropathy 30.5 IL10 IFNG CCL5
18 connective tissue disease 30.5 TNFSF13B IL1A IL10 IFNG
19 scabies 30.5 IL1A IL10
20 thrombocytopenia 30.4 TNFSF13B IL1A IL10 IFNG CD79A
21 viral pneumonia 30.4 IL10 CCL5
22 lymphopenia 30.4 IL2RA IL10 IFNG
23 aspergillosis 30.3 IL1A IL10 IFNG CCL5
24 hypereosinophilic syndrome 30.3 IL2RA IL10 IFNG CCL5
25 bacterial infectious disease 30.3 IL1A IL10 IFNG
26 mixed connective tissue disease 30.3 TNFSF13B IL10 IFNG
27 herpes zoster 30.2 IL10 IFNG CCR5
28 allergic disease 30.2 IL10 IFNG CCL5
29 dermatitis 30.2 IL1A IL10 IFNG CCL5
30 meningitis 30.2 IL1A IL10 IFNG CCL5
31 demyelinating disease 30.2 IL10 IFNG CCL5
32 cryoglobulinemia 30.2 TNFSF13B IFNG CD79A
33 encephalitis 30.1 IL10 CCR5 CCL5
34 pemphigus 30.1 TNFSF13B IL10 CD79A
35 conjunctival disease 30.0 IL1A IL10 IFNG CCL5
36 gingivitis 30.0 IL1A IL10 IFNG CCL5
37 lung disease 30.0 IL1A IL10 IFNG CCR5 CCL5
38 purpura 29.9 TNFSF13B IL10 IFNG CD79A
39 neuritis 29.9 IL10 IFNG CCR5 CCL5
40 hemolytic anemia 29.9 TNFSF13B IL2RA IL1A IL10 IFNG
41 diffuse large b-cell lymphoma 29.9 TNFSF13B IL10 CD79A
42 vaginitis 29.9 IL1A IL10 CCR5 CCL5
43 poliomyelitis 29.8 IL10 IFNG
44 hemophagocytic lymphohistiocytosis 29.8 IL2RA IL10 IFNG CCL5
45 pertussis 29.8 IL1A IL10 CCL5
46 sjogren syndrome 29.7 TNFSF13B IL2RA IL10 CD79A
47 alopecia areata 29.6 IL2RA IL1A IL10 IFNG
48 psoriasis 29.6 IL2RA IL1A IL10 IFNG CCL5
49 pulmonary fibrosis, idiopathic 29.6 IL1A IL10 IFNG CCL5
50 uveitis 29.5 IL2RA IL1A IL10 IFNG CCR5

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

58 31 (show top 50) (show all 55)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 poor wound healing 58 31 hallmark (90%) Very frequent (99-80%) HP:0001058
2 intermittent generalized erythematous papular rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0007432
3 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
4 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
5 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
6 erythema 58 31 frequent (33%) Frequent (79-30%) HP:0010783
7 abnormality of skin pigmentation 58 31 frequent (33%) Frequent (79-30%) HP:0001000
8 keratoconjunctivitis sicca 58 31 frequent (33%) Frequent (79-30%) HP:0001097
9 recurrent infections 58 31 frequent (33%) Frequent (79-30%) HP:0002719
10 nail dystrophy 58 31 frequent (33%) Frequent (79-30%) HP:0008404
11 bronchiectasis 58 31 frequent (33%) Frequent (79-30%) HP:0002110
12 xerostomia 58 31 frequent (33%) Frequent (79-30%) HP:0000217
13 onycholysis 58 31 frequent (33%) Frequent (79-30%) HP:0001806
14 recurrent corneal erosions 58 31 frequent (33%) Frequent (79-30%) HP:0000495
15 food intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0012537
16 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
17 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
18 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
19 flexion contracture 58 31 occasional (7.5%) Occasional (29-5%) HP:0001371
20 gastroesophageal reflux 58 31 occasional (7.5%) Occasional (29-5%) HP:0002020
21 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
22 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
23 hematuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000790
24 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
25 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
26 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
27 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
28 myalgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003326
29 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
30 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
31 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
32 skin vesicle 58 31 occasional (7.5%) Occasional (29-5%) HP:0200037
33 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
34 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
35 pneumothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0002107
36 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
37 fasciitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100537
38 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
39 phimosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001741
40 esophageal stricture 58 31 occasional (7.5%) Occasional (29-5%) HP:0002043
41 urinary bladder inflammation 58 31 occasional (7.5%) Occasional (29-5%) HP:0100577
42 morphea 58 31 occasional (7.5%) Occasional (29-5%) HP:0012344
43 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
44 wheezing 58 31 occasional (7.5%) Occasional (29-5%) HP:0030828
45 esophageal ulceration 58 31 occasional (7.5%) Occasional (29-5%) HP:0004791
46 bronchiolitis obliterans 58 31 occasional (7.5%) Occasional (29-5%) HP:0011946
47 entrapment neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012181
48 abnormal vagina morphology 31 occasional (7.5%) HP:0000142
49 airway obstruction 31 occasional (7.5%) HP:0006536
50 abnormality of the vagina 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CCL5 CCR5 CD79A IFNG IL10 IL1A
2 immune system MP:0005387 9.61 CCL5 CCR5 CD79A IFNG IL10 IL1A
3 neoplasm MP:0002006 9.02 CCR5 CD79A IFNG IL10 IL1A

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
2
Busulfan Approved, Investigational Phase 4 55-98-1 2478
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4 Antilymphocyte Serum Phase 4
5 Thymoglobulin Phase 4
6
Atorvastatin Approved Phase 3 134523-00-5 60823
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 32798 5311051
10
Budesonide Approved Phase 3 51333-22-3 63006 5281004
11
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
12
Hydroxychloroquine Approved Phase 3 118-42-3 3652
13
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
16
Mycophenolic acid Approved Phase 3 24280-93-1 446541
17
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
18
Inolimomab Investigational Phase 3 152981-31-2 5785
19 Anticholesteremic Agents Phase 3
20 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
21 Hypolipidemic Agents Phase 3
22 Lipid Regulating Agents Phase 3
23 Gastrointestinal Agents Phase 3
24 Antiemetics Phase 3
25 Antiparasitic Agents Phase 3
26 Antiprotozoal Agents Phase 3
27 Antimalarials Phase 3
28 Rho(D) Immune Globulin Phase 3
29 gamma-Globulins Phase 3
30 Respiratory System Agents Phase 3
31 Anti-Asthmatic Agents Phase 3
32 Bronchodilator Agents Phase 3
33 Janus Kinase Inhibitors Phase 2, Phase 3
34 Hormones Phase 3
35 Hormone Antagonists Phase 3
36 glucocorticoids Phase 3
37 Anti-Inflammatory Agents Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 Antirheumatic Agents Phase 3
40 Immunosuppressive Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Calcineurin Inhibitors Phase 3
43 Anti-Infective Agents Phase 3
44 Antifungal Agents Phase 3
45 Cyclosporins Phase 3
46 Dermatologic Agents Phase 3
47 Antitubercular Agents Phase 3
48
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
49
Sodium citrate Approved, Investigational Phase 2 68-04-2
50
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
2 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
3 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
4 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
5 Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors Unknown status NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus
6 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
7 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
8 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
9 Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
10 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
11 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
12 GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Recruiting NCT03584516 Phase 2, Phase 3 Itacitinib;Placebo;Methylprednisolone;Prednisone
13 Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE) Active, not recruiting NCT02959944 Phase 3 ibrutinib;Placebo;Prednisone
14 A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Active, not recruiting NCT03474679 Phase 3 Ibrutinib
15 A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac® (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD) Not yet recruiting NCT04289103 Phase 3
16 A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease Terminated NCT00298324 Phase 3 Myfortic;Prednisone and Cyclosporine
17 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
18 Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
19 Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease Unknown status NCT01158105 Phase 2 Bortezomib
20 Phase II Study for Treatment of Chronic Graft-Versus-Host Disease of the Liver or Lungs With Adjunct Extracorporeal Photoimmunotherapy Unknown status NCT00271869 Phase 2
21 Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Chronic Graft-versus-host Disease Unknown status NCT01765660 Phase 2
22 Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease Unknown status NCT01549665 Phase 1, Phase 2
23 A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease Unknown status NCT00972660 Phase 2 Prednisone and cyclosporine or primary therapies
24 A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease Unknown status NCT02385019 Phase 1, Phase 2
25 Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases Completed NCT02997280 Phase 2 Ruxolitinib Oral Tablet
26 A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease Completed NCT02195869 Phase 1, Phase 2 Ibrutinib
27 A Phase II Study of Pentostatin For the Treatment of High Risk or Refractory Chronic GVHD in Children Completed NCT00144430 Phase 2 Pentostatin
28 A Phase II Trial of Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Completed NCT00388362 Phase 2 Sirolimus;Prednisone
29 PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood Completed NCT01509560 Phase 2 Everolimus
30 Ixazomib for Treatment of Chronic Graft vs. Host Disease Completed NCT02513498 Phase 2 Ixazomib Citrate
31 Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease Completed NCT01161628 Phase 2 Rituximab
32 An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease Completed NCT00686855 Phase 2 Tacrolimus;Dexamethasone
33 A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease Completed NCT00815919 Phase 2 bortezomib;Prednisone
34 Carfilzomib for Treatment of Chronic Graft vs. Host Disease Completed NCT02491359 Phase 2 Carfilzomib
35 Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell Completed NCT01956903 Phase 1, Phase 2
36 Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Completed NCT02966301 Phase 2 Arsenic Trioxide Injectable Solution
37 Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease Completed NCT02040623 Phase 2 R348 Ophthalmic Solution, 0.2%;R348 Ophthalmic Solution, 0.5%
38 Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study - Completed NCT01862965 Phase 2 PredEver
39 Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab Completed NCT01135641 Phase 2 Rituximab;Ciclosporine;Corticosteroids
40 A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease Completed NCT00702689 Phase 2 Gleevec, STI571(Imatinib Mesylate)
41 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
42 A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation Completed NCT00770757 Phase 2 CC-4047
43 Reduction of Acute and Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem-cell Transplantation by Adapting Cyclosporine Doses According to Calcineurin Activity : a Proof-of-concept Trial Completed NCT00948727 Phase 2 Cyclosporine (CsA)
44 Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease. Completed NCT01222039 Phase 1, Phase 2
45 A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-Disease Completed NCT01557517 Phase 2 Clobetasol Oral Rinse;Placebo oral rinse
46 MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation Completed NCT02250300 Phase 1, Phase 2 MLN9708
47 A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease Completed NCT00074035 Phase 2 pentostatin
48 A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease Completed NCT00054613 Phase 2 Methoxsalen
49 Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease Completed NCT00391170 Phase 2 Topical Dexamethasone
50 An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation Completed NCT00186628 Phase 2 Rituximab;Anti-thymoglobulin, rabbit (ATG, rabbit ATG);Cyclosporine;Mycophenylate mofetil;Filgrastim;Granisetron;Solumedrol;Acetaminophen;Diphenhydramine;Hydrocortisone

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

40
Bone Marrow, Myeloid, T Cells, Bone, Eye, B Cells, Skin

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 4054)
# Title Authors PMID Year
1
Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. 54 61
19285638 2009
2
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. 61 54
16239431 2006
3
Granulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. 54 61
10975509 2000
4
Ibrutinib-induced acute kidney injury via interstitial nephritis. 61
33567947 2021
5
Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia. 61
33648437 2021
6
Severe cellulitis caused by Achromobacter xylosoxidans after allogeneic hematopoietic stem cell transplantation. 61
33468424 2021
7
Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. 61
33386599 2021
8
Problem-solving in clinical practice: breathing difficulty and muscle weakness following allogeneic haematopoietic stem cell transplantation. 61
32900776 2021
9
Continuation of systemic treatments and outcomes for patients with chronic graft-versus-host disease in the USA. 61
33504204 2021
10
Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation. 61
33385291 2021
11
Concurrent Reductions in Spirometry Predict Mortality and Bronchiolitis Obliterans in Chronic Graft-versus-Host Disease. 61
33147422 2021
12
Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. 61
33421199 2021
13
Determinants of cardiorespiratory fitness in very long-term survivors of allogeneic hematopoietic stem cell transplantation: a national cohort study. 61
32827056 2021
14
Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months. 61
33762107 2021
15
Ruxolitinib for the treatment of chronic GVHD and overlap syndrome in children and young adults. 61
33795598 2021
16
Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes following Allogeneic Hematopoietic Cell Transplantation. 61
33693799 2021
17
A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. 61
33734137 2021
18
Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide in Pediatric Hemophagocytic Lymphohistiocytosis. 61
33687579 2021
19
Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. 61
33415423 2021
20
High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. 61
33664462 2021
21
Salivary BPIFA proteins are altered in patients undergoing hematopoietic cell transplantation. 61
33682222 2021
22
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children. 61
33296531 2021
23
Oral acute graft versus host disease after donor lymphocyte infusions: Clinicopathological characterization in a monocenter cohort. 61
33187825 2021
24
β3-Adrenoreceptors as ROS Balancer in Hematopoietic Stem Cell Transplantation. 61
33799536 2021
25
Three resected cases of esophageal carcinoma considered as being secondary solid tumors after bone marrow transplantation. 61
33744998 2021
26
EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. 61
33675520 2021
27
Eosinophilic fasciitis (Shulman syndrome), a rare entity and diagnostic challenge, as a manifestation of severe chronic graft-versus-host disease: a case report. 61
33722291 2021
28
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. 61
33646302 2021
29
Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. 61
33775624 2021
30
Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis. 61
33615925 2021
31
Wnt/β-catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients. 61
33758171 2021
32
Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. 61
33781538 2021
33
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease. 61
33686248 2021
34
The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. 61
33785366 2021
35
Microbiota phylogenic analysis revealed decreased abundance of Faecalibacterium prausnitzii, an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease. 61
33785388 2021
36
Tear Lipid Metabolites As Potential Diagnostic Biomarkers for Ocular Chronic Graft-Versus-Host Disease. 61
33781517 2021
37
Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. 61
33811972 2021
38
Regarding chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation. 61
33704664 2021
39
Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. 61
33027805 2021
40
Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. 61
33710366 2021
41
Chronic oral graft-versus-host disease: induction and maintenance therapy with photobiomodulation therapy. 61
32666212 2021
42
Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft Versus Host Disease. 61
33781975 2021
43
Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. 61
33515310 2021
44
Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. 61
33789163 2021
45
Impact of total body irradiation based myeloablative conditioning regimen in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant: systematic review and meta-analysis. 61
33798768 2021
46
Fecal microbiota transplantation in patients with acute and chronic graft-versus-host disease-spectrum of responses and safety profile. Results from a prospective, multicenter study. 61
33326127 2021
47
Higher exercise tolerance early after allogeneic hematopoietic stem cell transplantation is the predictive marker for higher probability of later social reintegration. 61
33785825 2021
48
Current applications of platelet gels in wound healing-A review. 61
33749992 2021
49
Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. 61
33206383 2021
50
Large Granular Lymphocytosis With Cytopenias After Allogeneic Blood or Marrow Transplantation: Clinical Characteristics and Response to Immunosuppressive Therapy. 61
33781530 2021

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 TNFSF13B IL2RA IL1A IL10 IFNG CD79A
2
Show member pathways
13.42 TNFSF13B IL2RA IL1A IL10 IFNG CCR5
3
Show member pathways
13.34 TNFSF13B IL2RA IL1A IL10 IFNG CCL5
4
Show member pathways
13.18 TNFSF13B IL2RA IL1A IL10 CCR5 CCL5
5
Show member pathways
13.05 TNFSF13B IL2RA IL1A IL10 CCR5 CCL5
6
Show member pathways
12.91 TNFSF13B IL2RA IL1A IL10 IFNG CCR5
7
Show member pathways
12.64 IL2RA IL1A IFNG CCL5
8
Show member pathways
12.62 IL2RA IL1A IFNG CD79A
9
Show member pathways
12.62 TNFSF13B IL2RA IL1A IL10 IFNG
10
Show member pathways
12.5 TNFSF13B IL1A IL10 IFNG
11
Show member pathways
12.46 IL2RA IL10 IFNG CD79A
12
Show member pathways
12.43 IL1A IL10 IFNG CCR5
13
Show member pathways
12.41 IL2RA IL1A IL10 IFNG
14
Show member pathways
12.13 IL2RA IL10 CCR5 CCL5
15
Show member pathways
12.08 IL2RA IL1A IL10 IFNG
16 12.07 IL1A IL10 IFNG
17
Show member pathways
12.01 IL1A IL10 IFNG CCR5
18 11.87 TNFSF13B IL1A IFNG
19
Show member pathways
11.83 IL2RA IFNG CCR5
20 11.69 IL2RA IL10 IFNG CD79A
21 11.63 IL2RA IL10 IFNG
22 11.61 TNFSF13B IL2RA IL10 IFNG CD79A CCL5
23 11.52 TNFSF13B IL2RA IL10
24 11.43 TNFSF13B IL1A IFNG CCL5
25 11.3 IL2RA IL10 IFNG
26 11.21 IL1A IL10
27 11.18 IL2RA IFNG
28
Show member pathways
11.14 IL2RA IL10 IFNG
29
Show member pathways
11.12 IL2RA IFNG
30 11.1 IL2RA IFNG
31 11.07 IL10 IFNG
32 11.01 IL1A IL10 IFNG
33 10.95 IL1A IL10 CCR5 CCL5
34 10.93 IL1A IFNG
35 10.85 TNFSF13B IL1A IL10 CCL5

GO Terms for Chronic Graft Versus Host Disease

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.71 IL2RA IL1A CCR5 CCL5
2 cellular response to lipopolysaccharide GO:0071222 9.67 IL1A IL10 CCR5
3 cell surface receptor signaling pathway GO:0007166 9.55 IL2RA IFNG FCRL3 CD79A CCR5
4 B cell proliferation GO:0042100 9.52 IL10 CD79A
5 positive regulation of JAK-STAT cascade GO:0046427 9.51 IL10 CCL5
6 positive regulation of T cell proliferation GO:0042102 9.5 TNFSF13B IL2RA CCL5
7 dendritic cell chemotaxis GO:0002407 9.48 CCR5 CCL5
8 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IFNG
9 positive regulation of signaling receptor activity GO:2000273 9.43 IL10 IFNG
10 positive regulation of cytokine production GO:0001819 9.43 IL1A IL10 IFNG
11 positive regulation of MHC class II biosynthetic process GO:0045348 9.37 IL10 IFNG
12 cytokine-mediated signaling pathway GO:0019221 9.35 IL2RA IL1A IL10 CCR5 CCL5
13 immune response GO:0006955 9.17 TNFSF13B IL2RA IL1A IL10 IFNG CCR5

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNFSF13B IL1A IL10 IFNG CCL5
2 phosphatidylinositol phospholipase C activity GO:0004435 8.96 CCR5 CCL5

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....